By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


National Cancer Institute (NCI) 

NCI Public Inquiries Office
Building, 31, Room 10A03
31 Center Drive, MSC 2

Bethesda  Maryland  20892-2580  U.S.A.
Phone: 301-435-3848 Fax:



Maxygen, Inc. 

Genzyme General 

PanVera LLC 

Panacos Pharmaceuticals Inc.  Panacos has a CRADA with leading scientists at the National Cancer Institute to study the mechanism of HIV maturation inhibitors and to discover new antiviral drugs.

Company News
TRACON Pharma (TCON) Announces Top-Line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma 2/10/2017 8:49:11 AM
Kinetic River Corp. Delivers Potomac Modular Flow Cytometer To The NCI 2/7/2017 10:42:29 AM
Personal Genome Diagnostics Awarded NCI Contract To Develop Novel Diagnostic For Immuno-Oncology Drugs 2/1/2017 9:14:03 AM
Agenus (AGEN) Release: Company Announces Collaboration With The NCI To Evaluate The Combination Of Pembrolizumab (Keytruda, Merck & Co. (MRK)) With Prophage (Agenus Inc.) Autologous Vaccine 1/17/2017 10:02:30 AM
Xcovery Release: Company Joins NCI Formulary To Help Expedite Cancer Clinical Trials 1/17/2017 8:03:56 AM
ZIOPHARM Oncology (ZIOP) Release: Biopharma And Intrexon (XON) Announce Cooperative Research And Development Agreement With The NCI Utilizing Sleeping Beauty System To Generate T Cells Targeting Neoantigens 1/10/2017 10:42:37 AM
Threshold Pharma (THLD) And NCI To Collaborate On Drug Candidate TH-3424 12/19/2016 1:09:55 PM
Syndax Announces Collaboration With The NCI To Develop Entinostat And SNDX-6352 For The Treatment Of Cancer 12/14/2016 7:12:31 AM
Moleculin Biotech (MBRX) Presents Preclinical Data Of Novel Inhibitor Of Glycolysis At 28th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 12/13/2016 10:03:49 AM
Kite Pharma (KITE) Announces Publication Of T-Cell Therapy Targeting Mutant KRAS In Cancer By The NCI In The New England Journal of Medicine 12/12/2016 10:33:13 AM